Neoplasm Malignant
49
9
15
24
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.2%
4 terminated out of 49 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
8%
2 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (49)
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer
Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Evaluation of SAR408701 in Patients With Advanced Solid Tumors
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma